EDIÇÃO GENÉTICA NO REPARO DE GENES TUMORAIS EM TECIDOS MOLES: UMA REVISÃO BIBLIOGRÁFICA
DOI:
https://doi.org/10.36557/2674-8169.2024v6n8p4286-4298Palavras-chave:
Edição genética, Câncer, tecidos molesResumo
Introdução: A edição genética, uma tecnologia avançada que permite a modificação precisa do DNA, tem se mostrado uma ferramenta promissora no combate a tumores. Ao alterar diretamente as sequências genéticas responsáveis pelo desenvolvimento de câncer, essa técnica oferece novas possibilidades de tratamento, especialmente em casos onde os tumores são causados por mutações genéticas específicas. Esse estudo visa averiguar a aplicabilidade de tal tecnologia no âmbito clínico, bem como sua eficácia e segurança. Objetivo: Investigar, interpretar e revisar os achados sobre a edição genética no reparo de genes tumorais em tecidos moles, tal como discutir a viabilidade do tratamento, a fim de promover maior qualidade de vida e terapêutica adequada para cada caso individual dos pacientes. Metodologia: Utilizou-se a base Medical Literature Analysis and Retrieval System Online (MEDLINE/PubMed), sob os descritores genetic editing AND cancer, com seleção de artigos de revisão e artigos originais nos últimos 5 anos, seguindo os critérios de elegibilidade. Foram encontrados 533 artigos, dos quais foram selecionados 34 elegíveis.Resultados: Ao analisar os dados e evidências apresentados, infere-se que a edição do genoma humano é possível em escala clínica e apresenta bons resultados, se mostrando uma forte candidata para terapia quanto às neoplasias. No entanto, são necessários estudos adicionais para confirmar esses resultados e determinar sua eficácia em longo prazo.
Downloads
Referências
SHITARA, Kohei et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nature Medicine, p. 1-10, 2024.
PAL, Sumanta K. et al. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery, p. OF1-OF14, 2024.
BUYUKCELEBI, Kadir et al. Integrating leiomyoma genetics, epigenomics, and single-cell transcriptomics reveals causal genetic variants, genes, and cell types. Nature communications, v. 15, n. 1, p. 1169, 2024.
DZIUBAŃSKA-KUSIBAB, Paulina J.; NEVEDOMSKAYA, Ekaterina; HAENDLER, Bernard. Preclinical Anticipation of On-and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review. International Journal of Molecular Sciences, v. 25, n. 2, p. 705, 2024.
JAVADI, Marzieh; SAZEGAR, Hossein; DOOSTI, Abbas. Genome editing approaches with CRISPR/Cas9: the association of NOX4 expression in breast cancer patients and effectiveness evaluation of different strategies of CRISPR/Cas9 to knockout Nox4 in cancer cells. BMC cancer, v. 23, n. 1, p. 1155, 2023.
BRUEDIGAM, Claudia et al. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature Cancer, v. 5, n. 1, p. 47-65, 2024.
SPOLVERATO, Gaya et al. IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients–a cohort study. International Journal of Surgery, v. 109, n. 3, p. 323-332, 2023.
LEE, Myung Chang et al. A multiplexed in vivo approach to identify driver genes in small cell lung cancer. Cell reports, v. 42, n. 1, 2023.
HADDAD, Robert I. et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. Journal of Clinical Oncology, v. 41, n. 12, p. 2166-2180, 2023.
FOY, Susan P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature, v. 615, n. 7953, p. 687-696, 2023.
KHAN, Afreen; SARKAR, Esha. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer. Cancer Treatment and Research Communications, v. 33, p. 100641, 2022.
ATKINS, Michael B. et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134. Journal of Clinical Oncology, v. 41, n. 2, p. 186-197, 2023.
BYRD, Doratha A. et al. Circulating Bile Acids and Adenoma Recurrence in the Context of Adherence to a High-Fiber, High-Fruit and Vegetable, and Low-Fat Dietary Intervention. Clinical and Translational Gastroenterology, v. 13, n. 10, p. e00533, 2022.
WANG, Bo et al. Systematic comparison of ranking aggregation methods for gene lists in experimental results. Bioinformatics, v. 38, n. 21, p. 4927-4933, 2022.
JAFARPOUR, Sima et al. Unfavorable prognosis and clinical consequences of APOBEC3B expression in breast and other cancers: a systematic review and meta-analysis. Tumor Biology, v. 44, n. 1, p. 153-169, 2022.
CHESNEY, Jason A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. Journal of Clinical Oncology, v. 41, n. 3, p. 528-540, 2023.
FIZAZI, Karim et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Journal for immunotherapy of cancer, v. 10, n. 8, 2022.
LIU, Li et al. A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma. BMC cancer, v. 22, n. 1, p. 715, 2022.
STRAUSS, Kevin A. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature medicine, v. 28, n. 7, p. 1381-1389, 2022.
STRAUSS, Kevin A. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nature medicine, v. 28, n. 7, p. 1390-1397, 2022.
MOOLHUIJSEN, Loes ME et al. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients. Human Reproduction, v. 37, n. 7, p. 1544-1556, 2022.
ABDOLI SHADBAD, Mahdi et al. A systematic review on PD-1 blockade and PD-1 gene-editing of CAR-T cells for glioma therapy: from deciphering to personalized medicine. Frontiers in Immunology, v. 12, p. 788211, 2022.
DUMMER, Reinhard et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600–mutant unresectable or metastatic melanoma. Journal of Clinical Oncology, v. 40, n. 13, p. 1428-1438, 2022.
AXFORS, Cathrine et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC infectious diseases, v. 21, p. 1-23, 2021.
WANG, Zhenguang et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cellular & molecular immunology, v. 18, n. 9, p. 2188-2198, 2021.
CONNOLLY, Roisin M. et al. E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor–positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group. Journal of Clinical Oncology, v. 39, n. 28, p. 3171-3181, 2021.
GHORBANI, Atefeh; QUINLAN, Emma M.; LARIJANI, Mani. Evolutionary comparative analyses of DNA-editing enzymes of the immune system: from 5-dimensional description of protein structures to immunological insights and applications to protein engineering. Frontiers in Immunology, v. 12, p. 642343, 2021.
ANNAVAJHALA, Medini K. et al. Relationship of the esophageal microbiome and tissue gene expression and links to the oral microbiome: a randomized clinical trial. Clinical and Translational Gastroenterology, v. 11, n. 12, p. e00235, 2020.
SNEZHKINA, Anastasiya V. et al. Immunohistochemistry and mutation analysis of SDHx genes in carotid paragangliomas. International Journal of Molecular Sciences, v. 21, n. 18, p. 6950, 2020.
HUANG, Dennis et al. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. Advanced drug delivery reviews, v. 158, p. 17-35, 2020.
COOPER, Alissa J. et al. Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer. Clinical Cancer Research, v. 26, n. 15, p. 4072-4079, 2020.
BICAK, Mesude et al. Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human molecular genetics, v. 29, n. 10, p. 1581-1591, 2020.
STADTMAUER, Edward A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science, v. 367, n. 6481, p. eaba7365, 2020.
KONSTANTINOPOULOS, Panagiotis A. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. Journal of Clinical Oncology, v. 37, n. 30, p. 2786-2794, 2019.
DA SILVA SANTOS, Pamera; SILVA, Sandoval Gabriel Reis; DE CÁSSIA SOUZA, Tauany Maria. Comparação entre a eficácia da imunoterapia e da viroterapia oncolítica no tratamento do câncer hematológico: síntese de evidências. Brazilian Journal of Health Review, v. 6, n. 6, p. 29843-29850, 2023.
VOORDECKERS, Luana Barreto et al. Imunoterapia com células CAR-T como nova perspectiva de tratamento das neoplasias hematológicas. Brazilian Journal of Health Review, v. 7, n. 1, p. 2666-2678, 2024.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Farley Silva Duarte , Marttina Rossi Milão, Beatriz de Sousa Faria, Maria Eduarda Silvestre Carvalho, Lara Varela Bastos Pacheco
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.
